IDEAYA Biosciences, Inc. (IDYA)
IDYA Stock Price Chart
Explore IDEAYA Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze IDYA price movements and trends.
IDYA Company Profile
Discover essential business fundamentals and corporate details for IDEAYA Biosciences, Inc. (IDYA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 May 2019
Employees
131.00
Website
https://www.ideayabio.comCEO
Yujiro S. Hata
Description
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
IDYA Financial Timeline
Browse a chronological timeline of IDEAYA Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$1.06, while revenue estimate is $7.98m.
Earnings released on 5 May 2026
EPS came in at -$1.11 falling short of the estimated -$1.07 by -3.74%, while revenue for the quarter reached $6.56m , beating expectations by +30.20%.
Earnings released on 17 Feb 2026
EPS came in at -$0.94 surpassing the estimated -$0.95 by +1.23%, while revenue for the quarter reached $10.88m , beating expectations by +72.47%.
Earnings released on 4 Nov 2025
EPS came in at $1.33 surpassing the estimated -$0.95 by +240.60%, while revenue for the quarter reached $207.83m , beating expectations by +3.40k%.
Earnings released on 5 Aug 2025
EPS came in at -$0.88 falling short of the estimated -$0.85 by -3.53%.
Earnings released on 6 May 2025
EPS came in at -$0.82 falling short of the estimated -$0.75 by -9.33%.
Earnings released on 13 Feb 2025
EPS came in at -$1.49 falling short of the estimated -$0.67 by -122.39%, while revenue for the quarter reached $7.00m , beating expectations by +180.56%.
Earnings released on 4 Nov 2024
EPS came in at -$0.60 surpassing the estimated -$0.67 by +10.45%.
Earnings released on 6 Aug 2024
EPS came in at -$0.68 falling short of the estimated -$0.55 by -23.64%.
Earnings released on 7 May 2024
EPS came in at -$0.53 matching the estimated -$0.53.
Earnings released on 20 Feb 2024
EPS came in at -$0.52 falling short of the estimated -$0.49 by -6.12%, while revenue for the quarter reached $3.92m , missing expectations by -55.64%.
Earnings released on 7 Nov 2023
EPS came in at -$0.46 surpassing the estimated -$0.47 by +2.13%, while revenue for the quarter reached $8.04m , beating expectations by +2.53%.
Earnings released on 10 Aug 2023
EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%, while revenue for the quarter reached $3.54m , missing expectations by -21.42%.
Earnings released on 9 May 2023
EPS came in at -$0.49 surpassing the estimated -$0.51 by +3.92%, while revenue for the quarter reached $7.88m , beating expectations by +64.51%.
Earnings released on 7 Mar 2023
EPS came in at -$0.50 surpassing the estimated -$0.57 by +12.28%, while revenue for the quarter reached $4.02m , missing expectations by -42.54%.
Earnings released on 8 Nov 2022
EPS came in at $0.04 surpassing the estimated -$0.65 by +106.15%, while revenue for the quarter reached $29.70m , beating expectations by +347.15%.
Earnings released on 15 Aug 2022
EPS came in at -$0.57 matching the estimated -$0.57, while revenue for the quarter reached $5.85m , missing expectations by -23.95%.
Earnings released on 10 May 2022
EPS came in at -$0.36 surpassing the estimated -$0.41 by +12.20%, while revenue for the quarter reached $11.36m , beating expectations by +69.31%.
Earnings released on 15 Mar 2022
EPS came in at -$0.47 falling short of the estimated -$0.31 by -51.61%, while revenue for the quarter reached $2.96m , missing expectations by -67.00%.
Earnings released on 15 Nov 2021
EPS came in at -$0.31 falling short of the estimated -$0.29 by -6.90%, while revenue for the quarter reached $8.98m , missing expectations by -0.04%.
Earnings released on 10 Aug 2021
EPS came in at -$0.33 falling short of the estimated -$0.07 by -371.43%, while revenue for the quarter reached $8.76m , meeting expectations.
IDYA Stock Performance
Access detailed IDYA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
